{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:54Z","timestamp":1707525054163},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,28]]},"DOI":"10.7759\/cureus.39604","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T18:23:20Z","timestamp":1685298200000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab"],"prefix":"10.7759","author":[{"given":"Lorenzo Abednego B","family":"Adre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefino S","family":"Catangui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin Keith V","family":"Bondoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenerham M","family":"Abdurahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.01.048","article-title":"Treatment with tocilizumab in adult patients with moderate to critical COVID-19 pneumonia: a single-center retrospective study","volume":"117","author":"Radulescu A","year":"2022","unstructured":"Radulescu A, Istrate A, Muntean M. Treatment with tocilizumab in adult patients with moderate to critical COVID-19 pneumonia: a single-center retrospective study. Int J Infect Dis. 2022, 117:1-7. 10.1016\/j.ijid.2022.01.048","journal-title":"Int J Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005, 171:388-416. 10.1164\/rccm.200405-644ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection","year":"2020","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020, 20:e192-7. 10.1016\/S1473-3099(20)30483-7","journal-title":"Lancet Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew D","year":"2020","unstructured":"Mathew D, Giles JR, Baxter AE, et al.. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020, 369:eabc8511. 10.1126\/science.abc8511","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney OJ","year":"2020","unstructured":"McElvaney OJ, McEvoy NL, McElvaney OF, et al.. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020, 202:812-21. 10.1164\/rccm.202005-1583OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003629","article-title":"A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials","volume":"18","author":"Tierney JF","year":"2021","unstructured":"Tierney JF, Fisher DJ, Vale CL, et al.. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Med. 2021, 18:e1003629. 10.1371\/journal.pmed.1003629","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne JA","year":"2020","unstructured":"Sterne JA, Murthy S, Diaz JV, et al.. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020, 324:1330-41. 10.1001\/jama.2020.17023","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Gordon AC","year":"2021","unstructured":"Gordon AC, Mouncey PR, Al-Beidh F, et al.. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021, 384:1491-502. 10.1056\/NEJMoa2100433","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al.. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med. 2021, 384:1503-16. 10.1056\/NEJMoa2028700","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths","volume":"53","author":"Lai CC","year":"2020","unstructured":"Lai CC, Liu YH, Wang CY, et al.. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020, 53:404-12. 10.1016\/j.jmii.2020.02.012","journal-title":"J Microbiol Immunol Infect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone JH","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, et al.. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020, 383:2333-44. 10.1056\/NEJMoa2028836","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"FDA approves Roche\u2019s Actemra\/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome. (2017). Accessed. April 28, 2022: https:\/\/www.roche.com\/media\/releases\/med-cor-2017-08-30?utm_campaign=Sunday%20Newsletter&utm_source=hs_email&utm_medi...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25964","article-title":"Tocilizumab for the treatment of severe coronavirus disease 2019","volume":"92","author":"Alattar R","year":"2020","unstructured":"Alattar R, Ibrahim TB, Shaar SH, et al.. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020, 92:2042-9. 10.1002\/jmv.25964","journal-title":"J Med Virol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.05.20122622","article-title":"Tocilizumab as a therapeutic agent for critically Ill patients infected with SARS-CoV-2. [PREPRINT]","author":"Petrak RM","year":"2020","unstructured":"Petrak RM, Skorodin NC, Van Hise NW, et al.. Tocilizumab as a therapeutic agent for critically Ill patients infected with SARS-CoV-2. [PREPRINT]. medRxiv. 2020, 10.1101\/2020.06.05.20122622","journal-title":"medRxiv"},{"key":"ref15","article-title":"Clinical characteristics and outcomes of COVID-19 patients receiving immune-based therapy at a tertiary hospital: a retrospective cross-sectional study. [PREPRINT]","author":"Aborque JCJ","year":"2022","unstructured":"Aborque JCJ, Demot B, Cajulao TP, Bartolo S. Clinical characteristics and outcomes of COVID-19 patients receiving immune-based therapy at a tertiary hospital: a retrospective cross-sectional study. [PREPRINT]. HERDIN Plus. 2022, 1-10.","journal-title":"HERDIN Plus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar A","year":"2019","unstructured":"Pawar A, Desai RJ, Solomon DH, et al.. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019, 78:456-64. 10.1136\/annrheumdis-2018-214367","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott LJ","year":"2017","unstructured":"Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017, 77:1865-79. 10.1007\/s40265-017-0829-7","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro C","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Cavalli G, et al.. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020, 76:43-9. 10.1016\/j.ejim.2020.05.021","journal-title":"Eur J Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review","volume":"27","author":"Cortegiani A","year":"2021","unstructured":"Cortegiani A, Ippolito M, Greco M, et al.. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021, 27:52-66. 10.1016\/j.pulmoe.2020.07.003","journal-title":"Pulmonology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi G","year":"2020","unstructured":"Guaraldi G, Meschiari M, Cozzi-Lepri A, et al.. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020, 2:e474-84. 10.1016\/S2665-9913(20)30173-9","journal-title":"Lancet Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil AC","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al.. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016, 63:e61-111. 10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"ref22","unstructured":"STATA 13.1. (2013). https.\/\/www.stata.com\/support\/faqs\/resources\/history-of-stata\/."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104444","article-title":"Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care","volume":"129","author":"Quartuccio L","year":"2020","unstructured":"Quartuccio L, Sonaglia A, McGonagle D, et al.. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care. J Clin Virol. 2020, 129:104444. 10.1016\/j.jcv.2020.104444","journal-title":"J Clin Virol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.780872","article-title":"Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression","volume":"13","author":"Singh R","year":"2022","unstructured":"Singh R, Rathore SS, Khan H, et al.. Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022, 13:780872. 10.3389\/fendo.2022.780872","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2021.09.023","article-title":"Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis","volume":"67","author":"Kaushal K","year":"2022","unstructured":"Kaushal K, Kaur H, Sarma P, et al.. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022, 67:172-81. 10.1016\/j.jcrc.2021.09.023","journal-title":"J Crit Care"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00466-z","article-title":"D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study","volume":"8","author":"Yao Y","year":"2020","unstructured":"Yao Y, Cao J, Wang Q, et al.. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020, 8:49. 10.1186\/s40560-020-00466-z","journal-title":"J Intensive Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2022.07.009","article-title":"Predictors of mortality among inpatients with COVID-19 infection in a tertiary referral center in the Philippines","volume":"4","author":"Malundo AF","year":"2022","unstructured":"Malundo AF, Abad CL, Salamat MS, et al.. Predictors of mortality among inpatients with COVID-19 infection in a tertiary referral center in the Philippines. IJID Reg. 2022, 4:134-42. 10.1016\/j.ijregi.2022.07.009","journal-title":"IJID Reg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159309-prevalence-of-hospital-acquired-pneumonia-among-patients-with-severe-to-critical-covid-19-pneumonia-given-tocilizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:19Z","timestamp":1707508939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159309-prevalence-of-hospital-acquired-pneumonia-among-patients-with-severe-to-critical-covid-19-pneumonia-given-tocilizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.39604","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,28]]}}}